{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["82(7)"],"submitter":["Pichet Binette A"],"pubmed_abstract":["<h4>Importance</h4>While clinical disease stages remained largely unchanged in the 2024 update of the Alzheimer disease (AD) criteria, tau-positron emission tomography (PET) was introduced as a core biomarker and its spatial extent was incorporated into the revised biological stages of the disease. It is important to consider both the clinical and the biological stages and understand their discrepancies.<h4>Objective</h4>To compare individuals who have discrepant biological and clinical stages with those who have congruent stages in terms of copathologies, comorbidities, and demographics.<h4>Design, setting, and participants</h4>Participants were from the Swedish BioFINDER-2 (inclusion from 2017 through 2023) and the Alzheimer's Disease Neuroimaging Initiative (ADNI) (inclusion from 2015 t"],"journal":["JAMA neurology"],"pagination":["666-675"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12090069"],"repository":["biostudies-literature"],"pubmed_title":["Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease."],"pmcid":["PMC12090069"],"pubmed_authors":["Fox NC","Lacy K","Shen L","Crawford K","Bernard M","Di Benedetto J","Kaddurah-Daouk R","LoPresti B","Hoang I","Wan Y","Saito N","Strong J","Senjem M","Miller MJ","Carrillo M","Karlawish J","Thal L","Jin C","Villemagne V","DeCarli C","Okonkwo O","Gunter J","Glans I","Silverberg N","Parkins S","Lee VMY","Masliah E","Salazar J","Knaack A","Montine T","Yushkevich PA","Shaffer E","Taylor-Reinwald L","Pizzola J","Sachdev P","Fidell A","Frank R","Reyes C","Hansson O","Jenkins C","Reyes D","Nudelman K","Matoush L","Ossenkoppele R","Stomrud E","Moore-Weiss J","Walter S","Parchi P","Grill J","Tosun D","Gonzalez H","Fletcher E","Mattsson-Carlgren N","Lee EB","Robison J","Groot C","Molchan S","Cairns NJ","Schwarz C","Malone I","Ayo O","Buckholtz N","Neu S","Toga AW","Khachaturian Z","Thomas L","Masterman D","Cabrera Y","Conti C","Nir TM","Risacher SL","Felmlee J","Boatwright V","Aisen P","Clanton T","Mahboubi P","Foroud TM","Webb C","Weiner M","Snyder PJ","Pichet Binette A","Guzman V","Harkins K","Raman R","Glittenberg M","Talavera S","Zimmerman C","Craft H","Jo T","Forghanian-Arani A","Apostolova LG","Truran Sacrey D","Beckett L","Hedberg C","Jack CR","Borowski B","Fockler J","Kwang W","Landau S","Zetterberg H","Ajayi A","Koeppe RA","Ashford M","Weisensel T","Rossi Chen S","Green RC","Perrin R","Amaza H","Janelidze S","Palmqvist S","Seng Thao M","Kachaturian Z","Barnes L","Ho C","Largent E","Hergesheimer L","Potter Z","Tideman P","Adem Hussen K","Rabinovici G","Potter W","Bernhardt H","Korecka M","Nho K","Harvey D","Blennow K","Ward C","Diaz A","Franklin E","Ryan L","Das S","Choe M","Drake E","Kormos A","Reid R","Alzheimer’s Disease Neuroimaging Initiative","Adegoke O","Nosheny R","Rivera-Mindt M","Ogwang S","Rafii M","Morris J","Erickson C","Brylska M","Flenniken D","Salvado G","Jackson J","Jagust W","Saykin AJ","Hsiao JK","Magana F","Jahanshad N","van Westen D","Trojanowki JQ","Donohue M","Faber K","Jimenez G","Thompson P","Smith S","Smith R","Thomopoulos SI","Kubo Germano K","Shaw LM","Vemuri P","Kantarci K","Petersen R"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease.","description":"<h4>Importance</h4>While clinical disease stages remained largely unchanged in the 2024 update of the Alzheimer disease (AD) criteria, tau-positron emission tomography (PET) was introduced as a core biomarker and its spatial extent was incorporated into the revised biological stages of the disease. It is important to consider both the clinical and the biological stages and understand their discrepancies.<h4>Objective</h4>To compare individuals who have discrepant biological and clinical stages with those who have congruent stages in terms of copathologies, comorbidities, and demographics.<h4>Design, setting, and participants</h4>Participants were from the Swedish BioFINDER-2 (inclusion from 2017 through 2023) and the Alzheimer's Disease Neuroimaging Initiative (ADNI) (inclusion from 2015 t","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-06-01T06:19:32.514Z","creation":"2026-04-08T09:50:13.742Z"},"accession":"S-EPMC12090069","cross_references":{"pubmed":["40388185"],"doi":["10.1001/jamaneurol.2025.1100"]}}